Publicaciones científicas

Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha

Panizo C, Rifón J, Rodríguez-Wilhelmi P, Cuesta B, Rocha E.
Hematology Department, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain

Revista: Acta Haematologica

Fecha: 01-jun-1999

Hematología y Hemoterapia

Primary plasma cell leukemia (PCL) is a rare form of plasma cell neoplasm with a poor prognosis.

Conventional melphalan-based treatments have been most disappointing. We report the case of a 62-year-old man with a primary form of PCL treated with VAD combination achieving an objective response, and who received high-dose melphalan and autologous peripheral blood stem cell (PBSC) transplantation followed by interferon-alpha. During the remission time, lasting for 3 years, an infiltration by large granular lymphocytes (LGL) was noted in peripheral blood. However, when the number of LGL declined, a bone marrow relapse was observed.

The treatment for PCL and the possible role of these LGL on tumor cell control after autologous PBSC transplantation are discussed.

CITA DEL ARTÍCULO Acta Haematol. 1999;101(4):193-6



La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra


Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra


Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra